We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.00 | -2.26% | 43.25 | 43.00 | 43.50 | 44.25 | 43.25 | 44.25 | 929,586 | 14:21:09 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.13 | 122.66M |
From May 2019 to May 2024
TIDMAVCT
RNS Number : 6126Y
Avacta Group PLC
10 September 2015
10 September 2015
Avacta Group plc
("Avacta", the "Company" or the "Group")
Total Voting Rights
The Company would like to confirm that Avacta's issued share capital consists of 6,740,649,550 Ordinary Shares of 0.1p each with voting rights, and not 6,740,149,550 as was incorrectly stated in the Company's announcement on 3 September 2015.
The above figure of 6,740,649,550 should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules. The Company does not hold any shares in Treasury.
- Ends -
For further information:
Hot Features
Premium
Avacta Group plc Tel: +44 (0) 844 414
Tim Sykes, Chief Financial Officer 0452
www.avacta.com
Numis Securities Limited Tel: +44 (0) 207 260
Michael Meade / Freddie Barnfield - Nominated 1000
Adviser www.numiscorp.com
James Black - Corporate Broking
Media Enquiries Tel: +44 (0) 20 3727
FTI Consulting 1000
Simon Conway/Natalie Garland-Collins avacta@fticonsulting.com
About Avacta Group plc - www.avacta.com
Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through two divisions:
Avacta Animal Health Veterinary diagnostics reference laboratory
www.avactaanimalhealth.com and diagnostic kit provider.
Avacta Life Sciences Novel non-antibody affinity reagents
www.avactalifesciences.com called Affimers, with a wide range of
Life Science applications in diagnostics,
drug and biomarker discover and biotech
research and development.
--------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRLKLLBEKFLBBV
(END) Dow Jones Newswires
September 10, 2015 02:01 ET (06:01 GMT)
1 Year Avacta Chart |
1 Month Avacta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
